• Home
  • Business
  • Glenmark Recalls Blood Pressure Medication in the US Due to Dissolution Issues

Glenmark Recalls Blood Pressure Medication in the US Due to Dissolution Issues

Glenmark Pharmaceuticals is recalling over 6,500 bottles of Diltiazem Hydrochloride capsules in the US due to failing to meet dissolution specifications. This medication is used to treat high blood pressure.

Glenmark Recalls Blood Pressure Medication in the US Due to Dissolution Issues

Glenmark Recalls Blood Pressure Medication in theUS Due to Dissolution Issues. People taking medication to manage high blood pressure in the United States should be aware of a recent recall by Glenmark Pharmaceuticals. The Indian drugmaker is recalling over 6,500 bottles of Diltiazem Hydrochloride extended-release capsules due to failing to meet quality control standards.

 

The US Food and Drug Administration (USFDA) announced the recall in its latest Enforcement Report. The affected medication is the Diltiazem Hydrochloride capsules, a generic drug used to treat high blood pressure and angina (chest pain).

 

Reason for the Recall

The recall stems from concerns about the medication's dissolution specifications. Dissolution refers to the process by which a drug breaks down and releases its active ingredients into the body. Medications, especially extended-release capsules, are designed to dissolve at a specific rate to ensure a steady release of the drug into the bloodstream for prolonged effectiveness.

 

According to the USFDA report, a test conducted at the 12th-month mark of a long-term stability study for the medication indicated that it failed to meet the predetermined dissolution specifications. This raises concerns that the medication might not release the drug into the body at the intended rate, potentially leading to under-treatment of the targeted condition.

 

Risk Associated with the Recalled Medication

The USFDA has classified this as a Class II recall. This category signifies a situation where use of the medication may cause temporary or reversible health issues, or the possibility of serious adverse effects is remote.

 

However, it's important to note that if you are taking the recalled medication, there could be a potential for uncontrolled high blood pressure, which can lead to serious health complications if left untreated. These complications include stroke, heart attack, heart failure, and kidney problems.

 

What to Do if You Have the Recalled Medication

  • Check the medication bottle for the lot number and expiry date. The recall is specific to a particular lot that failed the dissolution test.
  • If you have the recalled medication (refer to the USFDA website for details on identifying the affected lot), discontinue use immediately.
  • Contact your doctor to discuss alternative treatment options for managing your high blood pressure.
  • Do not discard the recalled medication; instead, return it to the pharmacy where you purchased it.

 

Glenmark's Response to the Recall

Glenmark Pharmaceuticals initiated a Class II nationwide recall of the affected Diltiazem Hydrochloride capsules on March 26, 2024. The recall involves the New Jersey-based arm of the company, Glenmark Pharmaceuticals Inc.

The company has not issued any official statement regarding the reason for the failed dissolution test or the potential health risks associated with the recalled medication.

 

Maintaining Blood Pressure Control and Medication Safety

If you take medication for high blood pressure, it's crucial to adhere to your doctor's instructions and attend regular check-ups to monitor your blood pressure levels. This incident highlights the importance of robust quality control measures in pharmaceutical manufacturing to ensure patient safety.

 

Patients are advised to stay informed about medication recalls by following trusted sources like the USFDA website. You can sign up for email notifications to receive updates on the latest drug recalls.

 

By working together, patients, healthcare providers, and regulatory bodies can help ensure the safety and efficacy of medications.


TCS CEO Krithivasan's Compensation: Big Payday, But Not a Record Breaker

TCS CEO Krithivasan's Compensation: Big Payday, But Not a Record Breaker

Tata Consultancy Services (TCS) CEO K Krithivasan's first-year compensation package revealed, to...
Wipro Nears Settlement with Ex-Executives Dalal and Haque After Legal Tussle

Wipro Nears Settlement with Ex-Executives Dalal and Haque After Legal Tussle

Wipro is reportedly close to finalizing a settlement agreement with its former CFO Jatin Dalal and h...
Emirates Soars to Record Profits, Showers Employees with Bonuses

Emirates Soars to Record Profits, Showers Employees with Bonuses

Dubai's Emirates Group, parent company to Emirates Airline, shatters profit records for the seco...
Aditya Birla Fashion and Retail Strengthens Grip on Ethnic Wear Brand Tasva

Aditya Birla Fashion and Retail Strengthens Grip on Ethnic Wear Brand Tasva

 Aditya Birla Fashion and Retail Limited (ABFRL) has acquired an additional 5.54% stake in its ...
Warburg Pincus Makes Landmark Acquisition of Shriram Housing Finance

Warburg Pincus Makes Landmark Acquisition of Shriram Housing Finance

Private equity giant Warburg Pincus has agreed to acquire Shriram Housing Finance, a leading provide...
Blackstone Leads Consortium in Bid for Controlling Stake in Haldiram Snacks

Blackstone Leads Consortium in Bid for Controlling Stake in Haldiram Snacks

A consortium led by private equity giant Blackstone has submitted a bid to acquire a controlling sta...
TVS Holdings Makes Big Move in Consumer Finance with Home Credit India Acquisition

TVS Holdings Makes Big Move in Consumer Finance with Home Credit India Acquisition

TVS Holdings, a leading Indian conglomerate, has acquired a majority stake in Home Credit India, a p...
Byju's Shakes Up EdTech Market: Cuts Fees 30-40%, Boosts Sales Commissions

Byju's Shakes Up EdTech Market: Cuts Fees 30-40%, Boosts Sales Commissions

Byju's Shakes Up EdTech Market: Cuts Fees 30-40%, Boosts Sales Commissions ...
Indian CEOs Set to Make Their Mark at France's Choose France Forum

Indian CEOs Set to Make Their Mark at France's Choose France Forum

Seven Indian business leaders, including Sunil Bharti Mittal and N. Chandrasekharan, will meet with ...
Microsoft Makes Big Land Purchase in Hyderabad for Data Center Expansion

Microsoft Makes Big Land Purchase in Hyderabad for Data Center Expansion

Microsoft has acquired 48 acres of land in Hyderabad for a whopping Rs 267 crore, signaling a signif...